查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1422820

2024-2032 年男性性腺功能減退症市場報告（依治療類型、藥物傳遞、應用和地區）

Male Hypogonadism Market Report by Therapy Type, Drug Delivery, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球男性性腺功能減退症市場規模達到37億美元。展望未來， IMARC Group預計到2032年市場規模將達到56億美元，2024-2032年複合年成長率（CAGR）為4.54%。男性睪固酮缺乏症盛行率的大幅上升、患者群體對男性性腺功能減退症治療選擇的認知不斷提高以及健康意識的增強是推動市場的一些關鍵因素。

男性性腺功能減退症是一種睪丸無法產生足夠睪固酮的疾病，導致肌肉生長不足、毛髮生長受損、乳房發育受損、聲音低沉。這種疾病的特徵是男性缺乏睪固酮或精子產生。它是由與睪丸（原發性性腺功能減退症）或下丘腦-腦下垂體軸（繼發性性腺功能減退症）相關的疾病引起的。性腺機能減退症患者可能會遭受各種器官功能障礙以及生活品質下降，因為它源自於影響下視丘和腦下垂體的睪丸問題或疾病。男性性腺功能減退症可能是遺傳性的，也可能是後天性的，由荷爾蒙失衡、藥物或老化引起。幾種先天性酵素異常會導致全身不同程度的雄性激素抵抗。性腺功能減退症最常見於 60 歲以上的男性，其症狀和適應症也相應不同。

男性性腺功能減退症市場趨勢：

全球市場的主要動力是男性睪固酮缺乏症盛行率大幅上升以及不孕率上升。這可歸因於慢性生活方式障礙（包括肥胖和糖尿病）的發生率不斷增加。與此一致的是，更容易患有男性性腺功能減退症的老年人口的不斷擴大也為市場提供了動力。此外，患者群體對男性性腺功能減退症治療選擇的認知不斷提高，也是一個重要的生長誘導因素。多個國家的政府機構正在提高人們對性腺功能減退症治療方法的認知，包括睪固酮替代療法（TST）。然而，與外部睪固酮激素注射相關的嚴重不良反應是男性性腺功能減退症市場的一個重要的成長限制因素。相反，臨床試驗數量的增加和新治療方案的出現預計將在預測期內創造新的男性性腺功能減退症市場成長機會。除此之外，全球醫療基礎設施發展的持續技術進步正在為市場創造積極的前景。促進市場發展的其他一些因素包括快速城市化、日益增強的健康意識、高額醫療支出以及廣泛的研發（R&D）活動。

本報告回答的關鍵問題：

  • 迄今為止，全球男性性腺功能減退症市場表現如何，未來幾年將如何表現？
  • 全球男性性腺功能減退症市場的促進因素、限制因素和機會是什麼？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的男性性腺功能減退症市場？
  • 根據治療類型的市場分類是怎樣的？
  • 基於藥物輸送的市場區隔是什麼？
  • 基於應用程式的市場區隔是什麼？
  • 全球男性性腺功能減退症市場的競爭結構如何？
  • 全球男性性腺功能減退症市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球男性性腺功能減退症市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依治療類型

  • 睾酮替代療法
    • 市場走向
    • 市場預測
  • 促性腺激素釋放激素治療
    • 市場走向
    • 市場預測

第 7 章：市場細分：依藥物輸送

  • 外用凝膠
    • 市場走向
    • 市場預測
  • 注射劑
    • 市場走向
    • 市場預測
  • 經皮貼劑
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按應用

  • 卡爾曼症候群
    • 市場走向
    • 市場預測
  • 克氏綜合症
    • 市場走向
    • 市場預測
  • 腦下垂體疾病
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc
    • Endo International Plc
    • Ferring Holding SA
    • Grunenthal GmbH
    • Lilly USA, LLC (Eli Lilly and Company)
    • Pfizer Inc
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd
Product Code: SR112024A7206

Abstract

The global male hypogonadism market size reached US$ 3.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.54% during 2024-2032. A considerable rise in the prevalence of testosterone deficiency in males, the rising awareness of male hypogonadism treatment choices among the patient population, and increasing health consciousness represent some of the key factors driving the market.

Male hypogonadism is a medical condition in which the testes fail to produce enough testosterone, leading to a lack of muscle growth, impaired hair growth, breast development, as well as a lack of deepening of the voice. The medical condition is characterized by a lack of testosterone or spermatozoa production in men. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). An individual with hypogonadism may suffer from a variety of organ dysfunctions as well as a reduction in quality of life since it originates from a testicular problem or disorder that affects the hypothalamus and pituitary gland. Hypogonadism in men can be genetic or acquired, caused by hormonal imbalances, medications or aging. Several congenital enzyme abnormalities are responsible for causing different degrees of androgen resistance throughout the body. Hypogonadism is most common in men over the age of 60, and the symptoms and indications of the deficiency vary accordingly.

Male Hypogonadism Market Trends:

The global market is primarily driven by a considerable rise in the prevalence of testosterone deficiency in males, along with the growing infertility rates. This can be attributed to the increasing incidences of chronic lifestyle disorders, including obesity and diabetes. In line with this, the expanding geriatric population that is more susceptible to developing male hypogonadism is also providing an impetus to the market. Moreover, the rising awareness of male hypogonadism treatment choices among the patient population is also acting as a significant growth-inducing factor. Government bodies across several countries are promoting awareness of hypogonadism treatment methods, including testosterone replacement therapy (TST). However, severe adverse reactions associated with external testosterone hormone injections are acting as a significant growth-restraining factor for the male hypogonadism market. Conversely, the increasing number of clinical trials and the emergence of new treatment options are expected to create new male hypogonadism market opportunities for growth during the forecast period. Apart from this, continual technological advancements in the development of medical infrastructure on the global level are creating a positive outlook for the market. Some of the other factors contributing to the market include rapid urbanization, increasing health consciousness, high medical expenditure and extensive research and development (R&D) activities.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global male hypogonadism market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on therapy type, drug delivery and application.

Therapy Type Insights

Testosterone Replacement Therapy

Gonadotropin-Releasing Hormones Therapy

The report has provided a detailed breakup and analysis of the male hypogonadism market based on the therapy type. This includes testosterone replacement therapy and gonadotropin-releasing hormones therapy. According to the report, testosterone replacement therapy represented the largest segment.

Drug Delivery Insights

Topical Gels

Injectables

Transdermal Patches

Others

The report has provided a detailed breakup and analysis of the male hypogonadism market based on the drug delivery. This includes topical gels, injectables, transdermal patches, and others. According to the report, topical gels represented the largest segment.

Application Insights

Kallmann Syndrome

Klinefelters Syndrome

Pituitary Disorders

Others

A detailed breakup and analysis of the male hypogonadism market based on the application has also been provided in the report. This includes Kallmann Syndrome, Klinefelters Syndrome, pituitary disorders, and others.

Regional Insights

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for male hypogonadism. Some of the factors driving the North America male hypogonadism market include the growing geriatric population, rising prevalence of sedentary lifestyle and related medical conditions, increasing number of clinical trials, the emergence of new treatment options, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global male hypogonadism market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc, Endo International Plc, Ferring Holding S.A, Grunenthal GmbH, Lilly USA, LLC (Eli Lilly and Company), Pfizer Inc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd, etc.

Key Questions Answered in This Report:

  • How has the global male hypogonadism market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global male hypogonadism market?
  • What are the key regional markets?
  • Which countries represent the most attractive male hypogonadism markets?
  • What is the breakup of the market based on the therapy type?
  • What is the breakup of the market based on the drug delivery?
  • What is the breakup of the market based on the application?
  • What is the competitive structure of the global male hypogonadism market?
  • Who are the key players/companies in the global male hypogonadism market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Male Hypogonadism Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Testosterone Replacement Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Gonadotropin-Releasing Hormones Therapy
    • 6.2.1 Market Trends
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Delivery

  • 7.1 Topical Gels
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectables
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Transdermal Patches
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Kallmann Syndrome
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Klinefelters Syndrome
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Pituitary Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Endo International Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Ferring Holding S.A
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Grunenthal GmbH
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Lilly USA, LLC (Eli Lilly and Company)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Pfizer Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Sun Pharmaceutical Industries Limited
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Teva Pharmaceutical Industries Ltd
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio

List of Figures

  • Figure 1: Global: Male Hypogonadism Market: Major Drivers and Challenges
  • Figure 2: Global: Male Hypogonadism Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Male Hypogonadism Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Male Hypogonadism Market: Breakup by Therapy Type (in %), 2023
  • Figure 5: Global: Male Hypogonadism Market: Breakup by Drug Delivery (in %), 2023
  • Figure 6: Global: Male Hypogonadism Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Male Hypogonadism Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Male Hypogonadism (Testosterone Replacement Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Male Hypogonadism (Testosterone Replacement Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Male Hypogonadism (Gonadotropin-Releasing Hormones Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Male Hypogonadism (Gonadotropin-Releasing Hormones Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Male Hypogonadism (Topical Gels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Male Hypogonadism (Topical Gels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Male Hypogonadism (Injectables) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Male Hypogonadism (Injectables) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Male Hypogonadism (Transdermal Patches) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Male Hypogonadism (Transdermal Patches) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Male Hypogonadism (Other Drug Deliveries) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Male Hypogonadism (Other Drug Deliveries) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Male Hypogonadism (Kallmann Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Male Hypogonadism (Kallmann Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Male Hypogonadism (Klinefelters Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Male Hypogonadism (Klinefelters Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Male Hypogonadism (Pituitary Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Male Hypogonadism (Pituitary Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Male Hypogonadism (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Male Hypogonadism (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Male Hypogonadism Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Male Hypogonadism Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Male Hypogonadism Industry: Value Chain Analysis
  • Figure 79: Global: Male Hypogonadism Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Male Hypogonadism Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Male Hypogonadism Market Forecast: Breakup by Therapy Type (in Million US$), 2024-2032
  • Table 3: Global: Male Hypogonadism Market Forecast: Breakup by Drug Delivery (in Million US$), 2024-2032
  • Table 4: Global: Male Hypogonadism Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Male Hypogonadism Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Male Hypogonadism Market: Competitive Structure
  • Table 7: Global: Male Hypogonadism Market: Key Players